This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

This database contains 472 studies, archived under the term: "Pharmaceutical Interventions"

Click here to filter this large number of results.

No effect of donepezil on striatal dopamine release in mild to moderate Alzheimer’s disease
Objective: Work in experimental animals suggests that an interaction with dopaminergic networks might explain some of the therapeutic effects of the cholinesterase inhibitor class of drugs. This study aimed to test whether acute (single 5 mg) or 4–8 weeks (5–10 mg) of treatment with oral donepezil would elicit measurable striatal dopamine (DA) release in patients […]

A prospective study on the use of rivastigmine transdermal patch in Alzheimer’s dementia in a routine clinical setting
There is not much published literature on the use of rivastigmine patch in a “routine” clinical setting. Objectives: In this naturalistic longitudinal observational study we sought to evaluate the safety, tolerability and efficacy of the rivastigmine patch in patients with early and late onset moderate Alzheimer’s disease in a routine clinical setting. Methods: Out of […]

Changes in cognitive functions of patients with dementia of the Alzheimer type following long-term administration of donepezil hydrochloride: Relating to changes attributable to differences in apolipoprotein E phenotype
Aim: We conducted a study of changes in cognitive functions by long-term monitoring of dementia of Alzheimer type (DAT) patients to investigate the relationship between the progression of DAT symptoms and the presence of apolipoprotein (ApoE)4. Methods: The subjects consisted of 40 DAT patients who had been treated with donepezil for 3 years or more. […]

A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer disease: A post hoc analysis
Objective: To investigate the tolerability and efficacy of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer’s disease receiving concomitant memantine. Research design and methods: Post hoc analysis of a 25-week, randomized, prospective, open-label, parallel-group study. Patients receiving donepezil were switched to rivastigmine patches (4.6 mg/24 h) immediately or following a 7-day withdrawal for 4 […]

Behavioural abnormalities associated with rapid deterioration of language functions in semantic dementia respond to sertraline
Frontotemporal dementia (FTD) consists of three main clinical syndromes: (1) frontal variant FTD presenting predominantly with behavioral abnormalities, (2) semantic dementia presenting with fluent aphasic deficits and (3) primary progressive aphasia presenting with non-fluent aphasic deficits. We have observed that significant behavioral problems may occur in some patients with semantic dementia when both comprehension and […]

Acetylcholinesterase inhibitor treatment is associated with relatively slow cognitive decline in patients with Alzheimer’s disease and AD + DLB
Dementia can be caused by different diseases including Alzheimer’s disease (AD), dementia with Lewy bodies (DLB), or both (AD + DLB). University of Kentucky AD Center pathologically-diagnosed AD and AD + DLB cases were evaluated who had three or more longitudinal antemortem mental status examinations (n = 156). Patients with important concomitant pathology (n = […]

Efficacy and tolerability of Ginkgo biloba extract EGb 761® by type of dementia: Analyses of a randomised controlled trial
Secondary analyses of a randomised controlled trial were performed to find out whether treatment effects of Ginkgo biloba extract EGb 761® differed by type of dementia. Three hundred ninety-five patients aged 50 years or above, with dementia with neuropsychiatric features were treated with EGb 761® (240 mg/day) or placebo for 22 weeks. Patients scored between […]

Ginkgo biloba prevention trials: More than an ounce of prevention learned
Objective: To determine effectiveness of G biloba vs placebo in reducing the incidence of all-cause dementia and Alzheimer disease (AD) in elderly individuals with normal cognition and those with mild cognitive impairment (MCI). Design, Setting, and Participants: Randomized, double-blind, placebo-controlled clinical trial conducted in 5 academic medical centers in the United States between 2000 and […]

Long-term treatment of patients with Alzheimer’s disease in primary and secondary care: Results from an international survey
Objective: The International Outcomes Survey in Dementia (IOSID) was initiated to observe the effects of current standard of care for Alzheimer’s disease (AD) on patient outcomes and caregiver burden in a real-life setting. Research design and methods: This 2-year, international, prospective, longitudinal and observational cohort survey involved patients with mild-to-moderate AD (Mini-Mental State Examination [MMSE] […]

Treatment of vascular risk factors is associated with slower decline in Alzheimer disease
Background: There is growing evidence that vascular risk factors (VRF) contribute to cognitive decline. Whether their treatment can slow down the progression of Alzheimer disease (AD) remains unsettled. The aim of this observational study was to evaluate whether the treatment of VRF is associated with a slower cognitive decline in patients who have AD without […]

Try searching our database by another keyword...

To make a new query of the database, please enter your search terms below:

�

Contact Us